AVJ-301 Clinical Trial: A Clinical Evaluation of AVJ-301 (Absorb™ BVS) in Japanese Population
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 400 participants.
Also called NCT01844284
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 400 participants
- Sponsor
- Registry
-
NCT01844284
-
- Other papers using this trial's data
- A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan
- Bioresorbable Scaffold for Treatment of Coronary Artery Lesions: Intravascular Ultrasound Results From the ABSORB Japan Trial
- Long-Term Outcomes of Absorb Bioresorbable Vascular Scaffold vs. Everolimus-Eluting Metallic Stent - A Randomized Comparison Through 5 Years in Japan
- Randomized Comparison Between Everolimus-Eluting Bioresorbable Scaffold and Metallic Stent: Multimodality Imaging Through 3 Years
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01844284. Randomized; single masking; primary purpose treatment. Start 2013-04 (actual); primary completion 2015-01 (actual). Results posted on 2019-02-06.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- AVJ-301 Clinical Trial: A Clinical Evaluation of AVJ-301 (Absorb™ BVS) in Japanese Population
- Acronym
- ABSORB JAPAN
- Condition
- Coronary Artery Disease
- Condition
- Myocardial Ischemia
- Intervention (Device)
- XIENCE PRIME®/XIENCE Xpedition™
- Intervention (Device)
- Absorb™ BVS
- Lead sponsor
- Abbott Medical Devices
Record details
- Record id
cardio:ct-nct01844284- Content hash
b14fe6f26da323ce53ced604452efe814b1e36091be8b8efad4be1871b3cfd67